Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Standard and Individualized Treatment Model for Relapse and Refractory Lymphatic System Malignant Tumors

NCT02929615 is registered in ClinicalTrials.gov with Peking University as lead sponsor.

NCT NCT02929615
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02929615 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Standard and Individualized Treatment Model for Relapse and Refractory Lymphatic System Malignant Tumors
Lead sponsor
Peking University
Phase
Phase 4
Overall status
Unknown status
Start date
June 30, 2015
Completion date
March 31, 2018
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma